Analytical and quantitative cytology and histology · 2009
Expression of alpha-methylacyl coenzyme A racemase in partial and complete focal atrophy on prostate needle biopsies.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Worschech Adriana, Meirelles Luciana, Billis Athanase
Аннотация
OBJECTIVE: To describe the behavior of alpha-methylacyl coenzyme A racemase (AMACR) in focal atrophy including all subtypes. Focal prostatic atrophy is the benign lesion that most frequently mimicks adenocarcinoma particularly the partial variant.
STUDY DESIGN: We analyzed the immunohistochemical expression of AMACR in normal glands and acini of adenocarcinoma, partial atrophy and all variants of complete atrophy of a total of 1,198 acini on needle prostatic biopsies.
RESULTS: Partial atrophy showed negative and weak expression of AMACR in 143/190 (75.3%), and 47/190 (24.7%) acini, respectively. The secretory (luminal) compartment in all variants of complete atrophy showed aberrant immunohistochemical expression: AMACR negative, prostate-specific antigen negative and 34betaE12 positive, suggesting an intermediate phenotype for these cells.
CONCLUSION: No strong positivity was seen in partial atrophy; however, the absence of basal cells in 23.2% acini of partial atrophy and the weak positivity seen in 24.7% acini that overlaps with 22.5% acini with weak expression in adenocarcinoma may be a pitfall for the correct interpretation in the differential diagnosis of cancer. Recognizing the hematoxylin-eosin features of partial atrophy is still the most critical aspect in preventing a misdiagnosis of adenocarcinoma.
STUDY DESIGN: We analyzed the immunohistochemical expression of AMACR in normal glands and acini of adenocarcinoma, partial atrophy and all variants of complete atrophy of a total of 1,198 acini on needle prostatic biopsies.
RESULTS: Partial atrophy showed negative and weak expression of AMACR in 143/190 (75.3%), and 47/190 (24.7%) acini, respectively. The secretory (luminal) compartment in all variants of complete atrophy showed aberrant immunohistochemical expression: AMACR negative, prostate-specific antigen negative and 34betaE12 positive, suggesting an intermediate phenotype for these cells.
CONCLUSION: No strong positivity was seen in partial atrophy; however, the absence of basal cells in 23.2% acini of partial atrophy and the weak positivity seen in 24.7% acini that overlaps with 22.5% acini with weak expression in adenocarcinoma may be a pitfall for the correct interpretation in the differential diagnosis of cancer. Recognizing the hematoxylin-eosin features of partial atrophy is still the most critical aspect in preventing a misdiagnosis of adenocarcinoma.